Strategic Consulting

Building confidence through strategy, data, and regulatory insight.

We were particularly impressed with the efficiency and dedication of the MMS team and pleasantly surprised to see deliverables for review ahead of agreed upon deadlines in several instances.
Director, Clinical Data
Midsize Pharma

MMS Strategic Consulting brings together regulatory strategy, statistical consulting, and data expertise to support critical decisions across the drug development lifecycle. These consulting services combine regulatory strategy, statistical consulting and data expertise to help Sponsors make confident, evidence-based decisions that reduce risk and improve outcomes.

MMS strategic consultants collaborate across regulatory, clinical, statistical and biometrics functions to ensure that study designs are scientifically sound, operationally feasible and aligned with the expectations of regulators, investors and internal teams. Every engagement is focused on designing thoughtful trials, creating strong development strategies, and building plans that help move programs forward.

Integrated Support That Aligns Science With Strategy

MMS supports clients through the following:

  • Clinical development and trial design planning
  • End-to-end regulatory strategy and submission preparation
  • Advanced statistical modeling and risk assessment
  • Cross-functional gap analyses and implementation planning
  • Global regulatory pathway evaluation and health authority engagement

View our webinar on innovative trial design and regulatory strategy.

Statistical Consulting That Drives Stronger Trials

MMS statisticians work closely with regulatory experts to ensure that trial designs are ready to answer key questions and stand up to regulatory review. Through platforms like KerusCloud, MMS provides simulation-guided insight to test different trial scenarios, reduce uncertainty and improve planning.

Our depth of support includes:

  • Study design evaluation and protocol development
  • Estimand strategy and endpoint planning
  • Bayesian modeling and complex statistical methods
  • Synthetic control arms and Real-World Data (RWD) integration
  • Development plan optimization and investor decision support

Learn how data-focused outsourcing strategies are driving better trial outcomes for sponsors.

Regulatory Strategy That Supports Sound Decision-Making

MMS provides regulatory guidance starting with early-stage trials through to global marketing applications. The team applies knowledge of precedent and current standards to help Sponsors shape development plans that are clear and aligned with agency expectations. MMS has supported successful submissions to United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and other global agencies.

 

Our depth of support includes:

  • Investigational New Drug (IND), New Drug Application (NDA), Biologics License Application (BLA), and Marketing Authorisation Application (MAA) strategy and planning
  • Clinical trial application support
  • Health authority meeting preparation and representation
  • Regulatory gap assessments and roadmap creation
  • Strategic content development across modules

Explore insights from our experts on efficiencies for multi-agency submissions.

Continuity From Strategy to Execution

The same MMS statisticians, regulatory leads, and writers who support planning stay engaged through execution. This continuity helps avoid disconnects, keeps messaging consistent, and strengthens final submissions.

Sponsors choose MMS because they value responsive service, strong scientific support, and a true partnership approach. The MMS team is focused and ready to help you plan and deliver with confidence.

Get to know our values.

Suggested For You

perspectives

February 10th, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

February 5th, 2026

MMS Appoints FDA Alum Dr. Somya Dunn as Senior Medical Director, Safety Risk Management to Expand Leadership in REMS and Pharmacovigilance Solutions 

perspectives

February 3rd, 2026

A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

news

January 29th, 2026

Datacise® by MMS Named Finalist for Innovation in the Management of Clinical Data at the 2026 ACDM Awards 

ebook

January 27th, 2026

A Practical Guide to Expedited Regulatory Pathways

perspectives

January 27th, 2026

What Regulators Want to See in Surrogate Endpoints Today 

perspectives

January 20th, 2026

Behind the Scenes of Global Regulatory Submission Planning is a Symphony of Collaboration 

perspectives

January 13th, 2026

Making Clinical Trial Technology Work in Practice

fact sheet

December 17th, 2025

Advance Psychedelic Drug Development With Proven Regulatory and Data Expertise

fact sheet

December 17th, 2025

Agile Medical Writing Staff Augmentation When You Need Expertise Not Headcount

fact sheet

December 17th, 2025

Biometrics Solutions Fact Sheet: End-to-End Data Expertise for Complex Clinical Trials

whitepaper

December 17th, 2025

Estimands: Opportunity or Risk for Drug Developers?